Eli Lilly and Company (LLY) — closed signal from May 3, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 1, 2026.
Predicted vs. what happened
What happened
Reached its target in 25 days.
The thesis — published May 3, 2026
Eli Lilly looks like a growth company after another earnings beat, stronger demand for its obesity drug, and higher revenue guidance. Leadership in diabetes and obesity plus positive news on an oral obesity trial are pushing estimates higher. Because the stock jumped on the news and is extended, a period of consolidation would lower the chance of profit-taking before a clearer three-month advance.
Primary drivers
- Growing sales for obesity and diabetes products keep estimates moving up
- Earnings beat and raised guidance strengthen confidence in growth
- Positive results boost the outlook for an oral obesity medicine
- High valuation and recent big move make consolidation prudent
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.